Skip to content
Clinical Trials – home
LatviaBack to Latvia

Clinical trials in Sigulda – page 3

116 clinical trials in Sigulda, Latvia. Every trial is listed in the EU Clinical Trials Register and updated daily.

LatviaOur site in LatviaKliniskiePetijumi.lv(opens in a new tab)
Sigulda at a glance
116
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

116 trials in Sigulda

Open in trial search

Atrial fibrillation

Not yet recruiting

Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933 in Adults with Atrial Fibrillation Unsuitable for Oral Anticoagulation (Phase 3)

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:REGN9933
  • Sponsor:Regeneron Pharmaceuticals Inc.

Atrial fibrillation

Not yet recruiting

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.

Psoriatic arthropathy

Not yet recruiting

A study to evaluate the long-term safety and effectiveness of sonelokimab in patients with psoriatic arthritis

InvestigationalNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Osteoporosis postmenopausal

Not yet recruiting

Study on the Effects of BP16 and Denosumab in Women with Post-Menopausal Osteoporosis

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Ascorbic Acid
  • Sponsor:Curateq Biologics Private Limited

Diabetic retinal oedema

Not yet recruiting

Efficacy and safety of intravitreal MK-8748 versus aflibercept in adults with diabetic macular edema

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer+2

Not yet recruiting

Efficacy and Safety of Letrozole SIE Compared with Oral Letrozole, Both with Ribociclib, in Postmenopausal Women with HR‑Positive, HER2‑Negative Metastatic Breast Cancer

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Letrozole
  • Sponsor:Laboratorios Farmaceuticos Rovi S.A.

Infection prophylaxis

Not yet recruiting

Study of human normal immunoglobulin to prevent major infections in patients with hypogammaglobulinemia and autoimmune/rheumatic disease on B‑cell depletion therapy

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Octapharma Pharmazeutika Produktionsgesellschaft mbH

Primary biliary cholangitis

Not yet recruiting

Safety and Efficacy of Saroglitazar Magnesium in Patients with Primary Biliary Cholangitis: A Long‑Term Randomized Placebo‑Controlled Study

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years
  • Substances:Saroglitazar hemimagnesium
  • Sponsor:Zydus Therapeutics Inc.

Myasthenia gravis

Not yet recruiting

Efficacy and Safety of DNTH103 in Adults with Generalized Myasthenia Gravis: A Phase 3 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:DNTH103
  • Sponsor:Dianthus Therapeutics Inc.

Safety and Efficacy of Two Doses of OCUL101 Compared with Aflibercept in Patients with Neovascular Age‑Related Macular Degeneration

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:65+ years
  • Substances:Aflibercept
  • Sponsor:Shenzhen Oculgen Biomedical Technology Co. Ltd.

Evaluating the efficacy and safety of CRD-4730 in patients with heart failure with reduced ejection fraction

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:CRD-4730
  • Sponsor:Cardurion Pharmaceuticals Inc.

Atrial fibrillation

Not yet recruiting

Comparison of Etacizine and Propafenone for maintaining normal heart rhythm in patients with atrial fibrillation

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Ethacizine
  • Sponsor:Olpha AS

Other cities in Latvia

The busiest research cities in the country

All 18 cities in Latvia

Clinical research in Sigulda

What the registry says about research in the country

01 Diabetes Research

Clinical investigations focusing on advancing treatment options for patients with Type 2 Diabetes who aren't achieving optimal control with current medications.

  • Therapeutic Focus: Blood glucose management
  • Treatment Combination Studies
  • Metabolic Disease Research

The research evaluates the effectiveness of combining gliclazide MR with existing diabetes medications to improve glycemic control, particularly focusing on HbA1c reduction in patients with inadequate response to current treatments.

02 Metabolic Disorders

Innovative research exploring combination therapy approaches in metabolic disease management, specifically targeting patients with suboptimal response to standard treatments.

  • Medication Optimization
  • Glycemic Control Studies
  • Treatment Enhancement Research

This clinical investigation aims to advance our understanding of treatment optimization for patients requiring additional therapeutic support beyond initial medication regimens.

03 Treatment Efficacy

Comprehensive evaluation of treatment effectiveness in diabetes management, focusing on medication combinations to achieve better patient outcomes.

  • Safety Assessment
  • Clinical Response Monitoring
  • Long-term Effectiveness

The research examines both the efficacy and safety profiles of combined therapeutic approaches over a 24-week period, providing valuable insights into treatment optimization strategies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.